Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V
Laboratory of Neuroimmunology, Foundation Neurological Institute C Mondino, University of Pavia, Via Palestro 3, I-27100 Pavia, Italy.
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):123-6. doi: 10.1136/jnnp.74.1.123.
Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) gamma and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulatory treatment, and of healthy controls. After six months of treatment, different doses of IFN beta1a (Avonex or Rebif) decreased CD4+ (Th1, Th2) and CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months of glatiramer acetate (Copaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN beta1a produces sustained downmodulation of IFN gamma and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2, and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.
采用细胞内细胞因子流式细胞术分析了免疫调节治疗前后多发性硬化症患者及健康对照外周血中产生干扰素（IFN）γ和白细胞介素（IL）-4的T细胞百分比。治疗六个月后，不同剂量的IFNβ1a（阿沃尼单抗或利比）使CD4 +（Th1、Th2）和CD8 +（Tc1）细胞减少程度相似，而不影响Th1/Th2比值。醋酸格拉替雷（考帕松）治疗九个月后以及高剂量6-甲基泼尼松龙治疗六天后，这些T细胞亚群未发生改变。数据表明，IFNβ1a在体内可使产生IFNγ和IL-4的T细胞持续下调，这可能有助于其治疗效果；醋酸格拉替雷可能在不改变非特异性细胞免疫的情况下发挥作用；糖皮质激素诱导的淋巴细胞减少并不影响Th1、Th2和Tc1细胞的百分比；至少在外周血中，没有一种治疗方法会导致Th1向Th2转变，而这种转变可以解释它们各自的治疗效果。
